| Literature DB >> 28758016 |
Yutaka Yoshii1,2,3, Ken-Ichi Okuda1,2, Satomi Yamada1, Mari Nagakura1, Shinya Sugimoto1,2, Tetsuo Nagano4, Takayoshi Okabe4, Hirotatsu Kojima4, Takeo Iwamoto5, Kazuyoshi Kuwano3, Yoshimitsu Mizunoe1,2.
Abstract
Formation of bacterial biofilms on medical devices can cause severe or fatal infectious diseases. In particular, biofilm-associated infections caused by methicillin-resistant Staphylococcus aureus are difficult to eradicate because the biofilm is strongly resistant to antibiotics and the host immune response. There is no effective treatment for biofilm-associated infectionss, except for surgical removal of contaminated medical devices followed by antibiotic therapy. Here we show that norgestimate, an acetylated progestin, effectively inhibits biofilm formation by staphylococcal strains, including methicillin-resistant S. aureus, without inhibiting their growth, decreasing the selective pressure for emergence of resistance. 17-Deacetyl norgestimate, a metabolite of norgestimate, shows much weaker inhibitory activity against staphylococcal biofilm formation, indicating that the acetyl group of norgestimate is important for its activity. Norgestimate inhibits staphylococcal biofilm formation by inhibiting production of polysaccharide intercellular adhesin and proteins in the extracellular matrix. Proteome analysis of S. aureus indicated that norgestimate represses the expression of the cell wall-anchored protein SasG, which promotes intercellular adhesion, and of the glycolytic enzyme enolase, which plays a secondary role in biofilm formation. Notably, norgestimate induces remarkable changes in cell wall morphology, characterized by increased thickness and abnormal rippled septa. Furthermore, norgestimate increases the expression level of penicillin binding protein 2 and resensitizes methicillin-resistant S. aureus to β-lactam antibiotics. These results suggest that norgestimate is a promising lead compound for the development of drugs to treat biofilm-associated infections, as well as for its ability to resensitize methicillin-resistant S. aureus to β-lactam antibiotics.Entities:
Year: 2017 PMID: 28758016 PMCID: PMC5522392 DOI: 10.1038/s41522-017-0026-1
Source DB: PubMed Journal: NPJ Biofilms Microbiomes ISSN: 2055-5008 Impact factor: 7.290
Fig. 1Staphylococcal biofilm inhibitory activities of norgestimate (NGM) and 17-deacetylnorgestimate (17DN). a Structures of NGM and 17DN. b MR23 biofilm-inhibitory activities of NGM and 17DN. Data are presented as the mean ± SD (standard deviation) (n = 3). The graphs represent the average absorbance of the crystal violet-stained biofilms formed on 96-well plates. Photographs of representative wells are shown below the graphs. c Effects of NGM and 17DN on the growth of MR23. Cells were cultured in BHI broth under shaking conditions, with or without 50 μM of the test compound. d Fluorescence microscopy of PIA in a SH1000 biofilm. PIA and DNA were stained using WGA-Alexa488 (WGA; upper panels) and DAPI (lower panels), respectively. Arrowheads indicate the filamentous structural PIA. Scale bars = 5 μm. e Dot blot assay of PIA. f Quantification of ECM proteins. Data are presented as the mean ± SD (n = 3). *p < 0.01. In d–f, cells were cultured under biofilm-forming conditions, with or without 50 μM of the test compound, or 20 μg/mL of DspB. SH1000, S. aureus SH1000; MR23, S. aureus MR23; SE4, S. epidermidis SE4. Cont. control, NGM norgestimate, 17DN 17-deacetylnorgestimate, DspB dispersin B
Biofilm inhibitory activities of NGM and 17DN against various staphylococcal strains
| Strain | IC50 * value (μM) | |
|---|---|---|
| NGMa | 17DNb | |
| MSSA | ||
| MS3 | 22.5 | 92.2 |
| MS4-5 | 22.4 | 78.5 |
| MS18 | 13.1 | 75.6 |
| SH1000 | 15.6 | 49.0 |
| MRSA | ||
| MR2 | 13.4 | 76.5 |
| MR4 | 13.8 | 84.0 |
| MR11 | 12.0 | 62.7 |
| MR23 | 15.9 | 95.6 |
|
| ||
| SE4 | 15.1 | >100 |
| SE21 | 14.6 | >100 |
*Half maximal inhibitory concentration
a Norgestimate
b 17-deacetyl norgestimate
Fig. 2The effects of NGM on the proteome of S. aureus. a–c Two-dimensional (2-D) electrophoresis in the presence or absence of NGM or 17DN (a DMSO control; b NGM; c 17DN). d Identification of proteins, whose expressions were decreased in the presence of NGM on 2-D gel
Fig. 3The effects of NGM on enolase expression in the ECM. a Western blotting analysis of enolase expression in the ECM using an anti-enolase antibody. b Band intensities of western blotting analysis of enolase expression in the ECM. Data are presented as the mean ± SD (n = 3). *p < 0.01, **p < 0.05
Fig. 4The effects of NGM on cell morphology and expression of penicillin binding protein (PBP) 2 and PBP2a. a Cell wall thickness of MR23 and SH1000 cells treated with NGM or 17DN for 24 h. Data are presented as the mean ± SD (n = 50). *p < 0.01, **p < 0.05. b The frequency of abnormal septal formation in cells treated with NGM or 17DN for 24 h. *p < 0.01. Data are presented as the mean (n = 150). c Transmission electron microscopy (TEM) images. Representative cells with abnormal septal formation are shown (NGM and 17DN). Scale bars = 1 μm. d Fluorescence intensities of cells treated with FL-penicillin. Data are presented as the mean ± SD (n = 3) *p < 0.05. e Fluorescence microscopy of cell-associated FL-penicillin. Scale bars = 1 μm. f SDS-PAGE analysis of PBP2 detected using FL-penicillin. g Fluorescence intensities of the PBP2 bands detected using FL-penicillin. Data are presented as the mean ± SD (n = 3) *p < 0.05. h Western blotting analysis of PBP2a expression using an anti-PBP2a antibody. In these experiments, cells were cultured under biofilm-forming conditions, with or without 50 μM of the test compound
The effects of NGM on antibiotic susceptibility of S. aureus MR23 in Mueller–Hinton or BHIG broth
| Antibiotic | Mueller–Hinton | BHIG | ||||
|---|---|---|---|---|---|---|
| MIC* (μg/mL) | MIC (μg/mL) | |||||
| Control | NGMa | 17DNb | Control | NGM | 17DN | |
| β-lactam | ||||||
| Oxacillin | 32 | 4 | 4 | 8 | 0.5 | 0.5 |
| Ampicillin | 8 | 0.25 | 4 | 4 | 0.25 | 0.25 |
| Cefazolin | 16 | 1 | 4 | 4 | 1 | 1 |
| Cefmetazole | 16 | 8 | 16 | 8 | 2 | 2 |
| Flomoxef | 8 | 1 | 4 | 4 | 1 | 1 |
| Cefoxitin | 16 | 8 | 16 | 16 | 8 | 8 |
| Imipenem | 2 | 0.25 | 0.25 | 0.25 | 0.03 | 0.06 |
| Glycopeptide | ||||||
| Vancomycin | 2 | 1 | 1 | 2 | 2 | 2 |
| Teicoplanin | 2 | 1 | 1 | 2 | 1 | 1 |
| Oxazolidinone | ||||||
| Linezolid | 2 | 2 | 2 | 4 | 2 | 2 |
| Aminoglycoside | ||||||
| Gentamicin | 4 | 2 | 2 | >8 | >8 | >8 |
| Arbekacin | 0.5 | 0.25 | 0.25 | 2 | 1 | 1 |
| Tetracycline | ||||||
| Minocycline | <2 | <2 | <2 | <2 | <2 | <2 |
| Macrolide | ||||||
| Erythromycin | 0.25 | 0.25 | 0.25 | 0.5 | 0.5 | 0.5 |
| Lincomycin | ||||||
| Clindamycin | <0.06 | <0.06 | <0.06 | 0.12 | 0.12 | 0.12 |
| Fosfomycin | ||||||
| Fosfomycin | <32 | <32 | <32 | 32 | 64 | 64 |
| Fluoroquinolone | ||||||
| Levofloxacin | >4 | >4 | >4 | 4 | 4 | 4 |
| Sulfonamide | ||||||
| Sulfamethoxazole–Trimethoprim | <10 | <10 | <10 | 40 | 20 | 20 |
In these experiments, cells were cultured under biofilm-forming conditions, with 50 μM of the test compound
*Minimum inhibitory concentration
a Norgestimate
b 17-deacetyl norgestimate